Dr. Franklin L. Chen, M.D.
Hematology (Hematology (Internal Medicine) Physician)
- Medicare participating
At a glance
- Years since graduation
- 23
- In the NPI registry since
- 2008
- Medicare patients seen, 2024
- 142
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2008Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Hematology (Internal Medicine) Physician primary
NC license 2008-02063 -
Hematology & Oncology Physician
NC license 2008-02063
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Novant Health Forsyth Medical Center Winston-Salem, NC
- Novant Health Thomasville Medical Center Thomasville, NC
Medical groups
- Novant Health Thomasville Medical Center LLC (103 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 142
- Services billed
- 753
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Established patient office or other outpatient visit, 30-39 minutes | 139 | 45 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | 114 | 26 |
| Established patient office or other outpatient visit, 20-29 minutes | 55 | 35 |
| Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | 18 | 16 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 15 | 11 |
| New patient office or other outpatient visit, 60-74 minutes | 15 | 15 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Revlimid (lenalidomide) | 121 |
| Valacyclovir (valacyclovir hcl) Other prescribers in Winston Salem, NC | 87 |
| Hydroxyurea Other prescribers in Winston Salem, NC | 68 |
| Jakafi (ruxolitinib phosphate) | 62 |
| Calquence (acalabrutinib maleate) | 59 |
| Dexamethasone Other prescribers in Winston Salem, NC | 59 |
| Oxycodone Hcl Other prescribers in Winston Salem, NC | 55 |
| Venclexta (venetoclax) | 50 |
| Eliquis (apixaban) Other prescribers in Winston Salem, NC | 45 |
| Imbruvica (ibrutinib) | 35 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 20 companies reported 67 payments worth $48,061 in total to this clinician.
| GlaxoSmithKline, LLC. | $15,577 |
|---|---|
| Janssen Biotech, Inc. | $12,141 |
| AbbVie Inc. | $12,115 |
| Genzyme Corporation | $7,429 |
| Pfizer Inc. | $183 |
| Sobi, Inc | $129 |
| Beone Medicines USA, Inc. | $97.21 |
| Legend Biotech USA Inc. | $51.78 |
| Compensation for services other than consulting (speaking, faculty) | $44,372 |
|---|---|
| Food and Beverage | $2,028 |
| Travel and Lodging | $1,643 |
| Education | $17.16 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $4,200 |
| AbbVie Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $4,200 |
| Genzyme Corporation Jan 18, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $3,625 |
| Genzyme Corporation May 14, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $3,625 |
| Janssen Biotech, Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,300 |
| Janssen Biotech, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,300 |
| AbbVie Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $3,000 |
| GlaxoSmithKline, LLC. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
All 24 payments other than meals, newest first
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Oct 2, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $3,000 |
| AbbVie Inc. Jun 23, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $4,200 |
| GlaxoSmithKline, LLC. Jun 6, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Atlanta, GA | $437 |
| GlaxoSmithKline, LLC. Jun 4, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| Janssen Biotech, Inc. May 29, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Charleston, WV | $311 |
| GlaxoSmithKline, LLC. May 27, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $1,450 |
| GlaxoSmithKline, LLC. May 20, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Carrboro, NC | $108 |
| Janssen Biotech, Inc. May 15, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,300 |
| Genzyme Corporation May 14, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $3,625 |
| AbbVie Inc. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) VENCLEXTA · ONCOLOGY | $4,200 |
| GlaxoSmithKline, LLC. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| GlaxoSmithKline, LLC. May 12, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| Janssen Biotech, Inc. May 7, 2025 | Travel and Lodging RYBREVANT; CARVYKTI · Oncology · travel to Lynchburg, VA | $206 |
| Janssen Biotech, Inc. Apr 22, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $3,300 |
| AbbVie Inc. Apr 22, 2025 | Travel and Lodging VENCLEXTA · ONCOLOGY · travel to WILLIAMSBURG, VA · in-kind | $360 |
| GlaxoSmithKline, LLC. Apr 17, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Carrboro, NC · in-kind | $25.00 |
| Janssen Biotech, Inc. Apr 11, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $2,860 |
| GlaxoSmithKline, LLC. Apr 9, 2025 | Travel and Lodging OJJAARA · ONCOLOGY · travel to Johnson City, TN | $197 |
| Pfizer Inc. Apr 8, 2025 | Education ELREXFIO · ONCOLOGY · in-kind | $17.16 |
| GlaxoSmithKline, LLC. Apr 7, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $2,900 |
| Janssen Biotech, Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $1,100 |
| Janssen Biotech, Inc. Feb 20, 2025 | Compensation for services other than consulting (speaking, faculty) RYBREVANT; CARVYKTI · Oncology | $660 |
| Genzyme Corporation Jan 18, 2025 | Compensation for services other than consulting (speaking, faculty) SARCLISA · Oncology | $3,625 |
| GlaxoSmithKline, LLC. Jan 7, 2025 | Compensation for services other than consulting (speaking, faculty) OJJAARA · ONCOLOGY | $1,452 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 2 industry-funded studies in 2025, from 2 companies. The companies reported $57,684 in research payments for these studies, mostly to the institutions running them.
- Isatuximab in Combination With Lenalidomide and Dexamethasone in High-risk Smoldering Multiple Myeloma
Sanofi US Services Inc. · Active, not recruiting · NCT04270409 - A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly Diagnosed Multiple Myeloma Who Are Minimal Residual Disease Positive After Frontline Autologous St…
Janssen Research & Development, LLC
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.